Regorafenib, another tyrosine kinase inhibitor, was approved by the FDA as a third-line therapy for advanced GIST [14], is effective against tumors with c-kit exon 16, 17 or 18 mutations [15, 16, 17, 18, 19, 20]. Here, KIT is linked to gastrointestinal stromal tumor.